Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.08
NAS:ENDP's Cash-to-Debt is ranked lower than
95% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:ENDP: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ENDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.2 Max: No Debt
Current: 0.08
Equity-to-Asset 0.17
NAS:ENDP's Equity-to-Asset is ranked lower than
93% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:ENDP: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ENDP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.52 Max: 0.77
Current: 0.17
0.08
0.77
Piotroski F-Score: 4
Altman Z-Score: -1.03
Beneish M-Score: -4.25
WACC vs ROIC
1.88%
-25.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -84.38
NAS:ENDP's Operating Margin % is ranked lower than
86% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NAS:ENDP: -84.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ENDP' s Operating Margin % Range Over the Past 10 Years
Min: -86.57  Med: 21.38 Max: 30.74
Current: -84.38
-86.57
30.74
Net Margin % -82.93
NAS:ENDP's Net Margin % is ranked lower than
86% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:ENDP: -82.93 )
Ranked among companies with meaningful Net Margin % only.
NAS:ENDP' s Net Margin % Range Over the Past 10 Years
Min: -83.46  Med: -9.43 Max: 20.95
Current: -82.93
-83.46
20.95
ROE % -73.23
NAS:ENDP's ROE % is ranked lower than
89% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:ENDP: -73.23 )
Ranked among companies with meaningful ROE % only.
NAS:ENDP' s ROE % Range Over the Past 10 Years
Min: -85.73  Med: -12.88 Max: 20.43
Current: -73.23
-85.73
20.43
ROA % -20.72
NAS:ENDP's ROA % is ranked lower than
80% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:ENDP: -20.72 )
Ranked among companies with meaningful ROA % only.
NAS:ENDP' s ROA % Range Over the Past 10 Years
Min: -20.72  Med: -2.47 Max: 14.68
Current: -20.72
-20.72
14.68
ROC (Joel Greenblatt) % -512.19
NAS:ENDP's ROC (Joel Greenblatt) % is ranked lower than
88% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. NAS:ENDP: -512.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ENDP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -512.19  Med: 81.95 Max: 718.27
Current: -512.19
-512.19
718.27
3-Year Revenue Growth Rate 0.50
NAS:ENDP's 3-Year Revenue Growth Rate is ranked lower than
69% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NAS:ENDP: 0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ENDP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12  Med: 19.6 Max: 26.9
Current: 0.5
-12
26.9
GuruFocus has detected 3 Warning Signs with Endo International PLC $NAS:ENDP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ENDP's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ENDP Guru Trades in Q2 2016

Arnold Schneider 445,225 sh (New)
Joel Greenblatt 1,036,004 sh (New)
David Dreman 10,670 sh (+1247.22%)
Steven Cohen 2,521,434 sh (+1005.89%)
RS Investment Management 1,374,185 sh (+0.45%)
John Paulson 119,900 sh (unchged)
Wallace Weitz Sold Out
Diamond Hill Capital Sold Out
Andreas Halvorsen Sold Out
John Paulson 8,956,300 sh (-5.90%)
Paul Tudor Jones 17,296 sh (-73.04%)
Pioneer Investments 28,618 sh (-79.62%)
Jim Simons 11,005 sh (-98.07%)
» More
Q3 2016

ENDP Guru Trades in Q3 2016

Ray Dalio 887,293 sh (New)
Mario Gabelli 46,700 sh (New)
Larry Robbins 4,250,784 sh (New)
Jim Simons 206,060 sh (+1772.42%)
Paul Tudor Jones 59,815 sh (+245.83%)
Arnold Schneider 479,006 sh (+7.59%)
David Dreman 10,670 sh (unchged)
Pioneer Investments 28,618 sh (unchged)
John Paulson 7,953,900 sh (-11.19%)
Steven Cohen 1,762,300 sh (-30.11%)
Joel Greenblatt 28,677 sh (-97.23%)
» More
Q4 2016

ENDP Guru Trades in Q4 2016

Jim Simons 1,525,860 sh (+640.49%)
Ray Dalio 1,537,036 sh (+73.23%)
Arnold Schneider 559,211 sh (+16.74%)
Mario Gabelli 47,500 sh (+1.71%)
Pioneer Investments 28,618 sh (unchged)
Larry Robbins 4,250,784 sh (unchged)
David Dreman Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
John Paulson 7,839,900 sh (-1.43%)
» More
Q1 2017

ENDP Guru Trades in Q1 2017

Francis Chou 950,000 sh (New)
Steven Cohen 1,775,500 sh (New)
Joel Greenblatt 744,425 sh (New)
Paul Tudor Jones 114,416 sh (New)
Ray Dalio 3,825,502 sh (+148.89%)
Larry Robbins 10,378,390 sh (+144.15%)
Mario Gabelli 59,400 sh (+25.05%)
Arnold Schneider 642,311 sh (+14.86%)
Pioneer Investments 28,618 sh (unchged)
Jim Simons Sold Out
John Paulson 7,838,900 sh (-0.01%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:IRWD, NAS:MDCO, OTCPK:SWPIF, NAS:PCRX, OTCPK:EVTCY, NAS:HZNP, NAS:SUPN, NAS:OPK, NAS:RDUS, NAS:PAHC, NYSE:MNK, NAS:EGRX, NYSE:DPLO, NAS:AKRX, NAS:IPXL, NAS:MNTA, NYSE:CTLT, OTCPK:KHTRF, OTCPK:NPPNY, OTCPK:TWMJF » details
Traded in other countries:ENDP.Canada, EO7.Germany,
Headquarter Location:Ireland
Endo International PLC is a specialty healthcare company. The Company is engaged in developing, manufacturing, marketing and distribution of branded pharmaceutical and generic products as well as medical devices.

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. Recent acquisitions of Auxilium and Par, however, have increased the company's presence in urology and generics, respectively. Branded drugs represent approximately 30% of revenue with the remainder in generics.

Guru Investment Theses on Endo International PLC

Weitz Value Fund Comments on Endo International - Apr 27, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) left less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter of 2016 and refocus our capital in more attractive opportunities.



From Weitz Value Fund first quarter 2017 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jan 26, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Endo - Nov 08, 2016

Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Weitz Value Fund Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) left less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter of 2016 and refocus our capital in more attractive opportunities. Read more...
Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities. Read more...
Wally Weitz Comments on Endo Guru stock highlight
Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities in 7 companies
Introduction Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities with 7 companies
Introduction Read more...
Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.
From Read more...
Wally Weitz Drops Falling Drug Stock Endo but Sees 'Upside Potential' Possibly short-term headwinds prompted 75 percent market sell-off this year
Wally Weitz, founder and chief investment officer of Weitz Investment Management, informed clients via a one-off note Thursday that his firm exited it entire position in pharmaceutical company Endo International, whose stock has dwindled to a quarter of its market value year to date. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 3.73
ENDP's Forward PE Ratio is ranked higher than
97% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. ENDP: 3.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.31
ENDP's PB Ratio is ranked higher than
91% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ENDP: 1.31 )
Ranked among companies with meaningful PB Ratio only.
ENDP' s PB Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.5 Max: 17.5
Current: 1.31
0.53
17.5
PS Ratio 0.70
ENDP's PS Ratio is ranked higher than
90% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ENDP: 0.70 )
Ranked among companies with meaningful PS Ratio only.
ENDP' s PS Ratio Range Over the Past 10 Years
Min: 0.54  Med: 2.24 Max: 6.03
Current: 0.7
0.54
6.03
Price-to-Free-Cash-Flow 4.86
ENDP's Price-to-Free-Cash-Flow is ranked higher than
91% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. ENDP: 4.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENDP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.76  Med: 9.39 Max: 242.43
Current: 4.86
3.76
242.43
Price-to-Operating-Cash-Flow 3.89
ENDP's Price-to-Operating-Cash-Flow is ranked higher than
92% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. ENDP: 3.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENDP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.01  Med: 8.99 Max: 423.65
Current: 3.89
3.01
423.65
EV-to-EBIT -3.05
ENDP's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. ENDP: -3.05 )
Ranked among companies with meaningful EV-to-EBIT only.
ENDP' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.3  Med: 8 Max: 77.3
Current: -3.05
-33.3
77.3
EV-to-EBITDA -4.37
ENDP's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. ENDP: -4.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -139  Med: 7.95 Max: 29.3
Current: -4.37
-139
29.3
Current Ratio 1.13
ENDP's Current Ratio is ranked lower than
89% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ENDP: 1.13 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.88 Max: 3.55
Current: 1.13
0.84
3.55
Quick Ratio 0.87
ENDP's Quick Ratio is ranked lower than
86% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ENDP: 0.87 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.63 Max: 3.34
Current: 0.87
0.61
3.34
Days Inventory 84.46
ENDP's Days Inventory is ranked higher than
64% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. ENDP: 84.46 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 80.55  Med: 99.98 Max: 148.08
Current: 84.46
80.55
148.08
Days Sales Outstanding 61.63
ENDP's Days Sales Outstanding is ranked lower than
60% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ENDP: 61.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 98.15 Max: 171.52
Current: 61.63
71.33
171.52
Days Payable 13.63
ENDP's Days Payable is ranked lower than
92% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. ENDP: 13.63 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 17.55  Med: 120.4 Max: 300.35
Current: 13.63
17.55
300.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.60
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ENDP: -24.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -4.75 Max: 4.7
Current: -24.6
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.58
ENDP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ENDP: 0.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENDP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.39  Med: 0.72 Max: 2.28
Current: 0.58
0.39
2.28
Price-to-Median-PS-Value 0.31
ENDP's Price-to-Median-PS-Value is ranked higher than
96% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ENDP: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENDP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.37 Max: 3.72
Current: 0.31
0.27
3.72
Earnings Yield (Greenblatt) % -32.79
ENDP's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ENDP: -32.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENDP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 8.2 Max: 26.8
Current: -32.79
1.3
26.8
Forward Rate of Return (Yacktman) % 40.09
ENDP's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. ENDP: 40.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENDP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 30.7 Max: 63.3
Current: 40.09
4.3
63.3

More Statistics

Revenue (TTM) (Mil) $4,084
EPS (TTM) $ -15.21
Beta-0.28
Short Percentage of Float9.67%
52-Week Range $9.70 - 24.93
Shares Outstanding (Mil)223.11

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,502 3,300 3,316
EPS ($) 3.47 3.30 3.48
EPS without NRI ($) 3.47 3.30 3.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-0.36%
Dividends per Share ($)
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Francis Chou Buys Pharmaceutical Stocks, Including Valeant May 17 2017 
Endo to Present at UBS Global Healthcare Conference May 01 2017 
Weitz Value Fund Comments on Endo International Apr 27 2017 
Endo to Announce First-Quarter 2017 Financial Results Apr 25 2017 
Endo International plc Announces Pricing of Private Offering of Senior Secured Notes Apr 12 2017 
Endo International plc Announces Proposed Private Offering of Senior Secured Notes Apr 10 2017 
Endo International plc Announces Plan to Refinance Existing Credit Agreement Apr 05 2017 
Aytu BioScience May Lead the Way in Low T Feb 28 2017 
Weitz Funds Comments on Endo International Jan 26 2017 
4 Stocks Reach Their 3-Year Lows Jan 21 2017 

More From Other Websites
Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts May 25 2017
Today's Research Reports on Stocks to Watch: Endo International and Helios and Matheson Analytics May 24 2017
Valeant Pharmaceuticals: Intrigued…Really? May 19 2017
BDSI CEO on Belbuca revenue potential: We're on an upward trend May 16 2017
New York county sues Purdue, J&J over opioid marketing May 15 2017
These Stocks Show Change of Direction May 15 2017
Edited Transcript of ENDP earnings conference call or presentation 9-May-17 12:30pm GMT May 13 2017
Today's Research Reports on Stocks to Watch: Endo International and Valeant Pharmaceuticals May 10 2017
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance May 09 2017
Here's What's Behind Endo International plc's Rally Today May 09 2017
Endo (ENDP) Q1 Earnings Beat Estimates, Revenues in Line May 09 2017
Investor Network: Endo International Plc to Host Earnings Call May 09 2017
Endo reports 1Q loss May 09 2017
Endo profit beats on strong sales of generic drugs May 09 2017
Endo posts 7.7 percent rise in quarterly revenue May 09 2017
Endo Reports First-Quarter 2017 Financial Results May 09 2017
4 Drug Stocks Poised to Beat this Earnings Season May 08 2017
[$$] Suits Dog Guggenheim Chief May 06 2017
Generic Drug Industry Headwinds Lead to Moat Downgrades May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)